-
Something wrong with this record ?
Cranberry fruit powder (Flowens™) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study
A. Vidlar, V. Student, J. Vostalova, E. Fromentin, M. Roller, V. Simanek, V. Student,
Language English Country Germany
Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 1997-02-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-02-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-02-01 to 1 year ago
- MeSH
- Time Factors MeSH
- Double-Blind Method MeSH
- Phytotherapy methods MeSH
- Prostatic Hyperplasia complications physiopathology therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Urination physiology MeSH
- Follow-Up Studies MeSH
- Fruit * MeSH
- Powders therapeutic use MeSH
- Lower Urinary Tract Symptoms etiology physiopathology therapy MeSH
- Vaccinium macrocarpon * MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia increase with age. To date, several medications are available to treat LUTS, including herbal remedies which offer less side effects but lack robust efficacy studies. METHODS: This 6-month, randomized, double-blind, placebo-controlled study aimed at evaluating the dose effect of 250 or 500 mg cranberry powder (Flowens™) on LUTS and uroflowmetry in men over the age of 45. A total of 124 volunteers with PSA levels <2.5 ng/mL and an international prostate symptoms score (IPSS) score ≥8 were recruited and randomized. The primary outcome measure was the IPSS, evaluated at 3 and 6 months. Secondary outcome measures included quality of life, bladder volume (Vol), maximum urinary flow rate (Q max), average urinary flow rate (Q ave), ultrasound-estimated post-void residual urine volume (PVR), serum prostate-specific antigen, selenium, interleukin 6, and C-reactive protein at 6 months. RESULTS: After 6 months, subjects in both Flowens™ groups had a lower IPSS (-3.1 and -4.1 in the 250- and 500-mg groups, p = 0.05 and p < 0.001, respectively) versus the placebo group (-1.5), and a dose-response effect was observed. There were significant differences in Q max, Q ave, PVR, and Vol in the Flowens™ 500-mg group versus baseline (p < 0.05). A dose-dependent effect on Vol was observed, as well as on PVR, for participants with a nonzero PVR. There was no effect on clinical chemistry or hematology markers. CONCLUSIONS: Flowens™ showed a clinically relevant, dose-dependent, and significant reduction in LUTS in men over 45.
Department of Urology University Hospital Olomouc Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17001129
- 003
- CZ-PrNML
- 005
- 20170117124458.0
- 007
- ta
- 008
- 170103s2016 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00345-015-1611-7 $2 doi
- 024 7_
- $a 10.1007/s00345-015-1611-7 $2 doi
- 035 __
- $a (PubMed)26049866
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Vidlar, Ales $u Department of Urology, University Hospital, Olomouc, Czech Republic.
- 245 10
- $a Cranberry fruit powder (Flowens™) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study / $c A. Vidlar, V. Student, J. Vostalova, E. Fromentin, M. Roller, V. Simanek, V. Student,
- 520 9_
- $a BACKGROUND: Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia increase with age. To date, several medications are available to treat LUTS, including herbal remedies which offer less side effects but lack robust efficacy studies. METHODS: This 6-month, randomized, double-blind, placebo-controlled study aimed at evaluating the dose effect of 250 or 500 mg cranberry powder (Flowens™) on LUTS and uroflowmetry in men over the age of 45. A total of 124 volunteers with PSA levels <2.5 ng/mL and an international prostate symptoms score (IPSS) score ≥8 were recruited and randomized. The primary outcome measure was the IPSS, evaluated at 3 and 6 months. Secondary outcome measures included quality of life, bladder volume (Vol), maximum urinary flow rate (Q max), average urinary flow rate (Q ave), ultrasound-estimated post-void residual urine volume (PVR), serum prostate-specific antigen, selenium, interleukin 6, and C-reactive protein at 6 months. RESULTS: After 6 months, subjects in both Flowens™ groups had a lower IPSS (-3.1 and -4.1 in the 250- and 500-mg groups, p = 0.05 and p < 0.001, respectively) versus the placebo group (-1.5), and a dose-response effect was observed. There were significant differences in Q max, Q ave, PVR, and Vol in the Flowens™ 500-mg group versus baseline (p < 0.05). A dose-dependent effect on Vol was observed, as well as on PVR, for participants with a nonzero PVR. There was no effect on clinical chemistry or hematology markers. CONCLUSIONS: Flowens™ showed a clinically relevant, dose-dependent, and significant reduction in LUTS in men over 45.
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a následné studie $7 D005500
- 650 12
- $a ovoce $7 D005638
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a symptomy dolních močových cest $x etiologie $x patofyziologie $x terapie $7 D059411
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a fytoterapie $x metody $7 D008517
- 650 _2
- $a prášky, zásypy, pudry $x terapeutické užití $7 D011208
- 650 _2
- $a hyperplazie prostaty $x komplikace $x patofyziologie $x terapie $7 D011470
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a močení $x fyziologie $7 D014554
- 650 12
- $a Vaccinium macrocarpon $7 D029799
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Student, Vladimir $u Department of Urology, University Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Vostalova, Jitka $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Fromentin, Emilie $u NATUREX-DBS, 375 Huyler Street, South Hackensack, NJ, USA. e.fromentin@naturex.com.
- 700 1_
- $a Roller, Marc $u NATUREX SA, 250 Rue Pierre Bayle, 84911, Avignon, France.
- 700 1_
- $a Simanek, Vilím $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Student, Vladimir $u Department of Urology, University Hospital, Olomouc, Czech Republic.
- 773 0_
- $w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 34, č. 3 (2016), s. 419-24
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26049866 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170103 $b ABA008
- 991 __
- $a 20170117124604 $b ABA008
- 999 __
- $a ok $b bmc $g 1180269 $s 961696
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 34 $c 3 $d 419-24 $e 20150607 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
- LZP __
- $a Pubmed-20170103